<DOC>
	<DOCNO>NCT00326716</DOCNO>
	<brief_summary>To determine dose regimen atazanavir ( ATV ) / ritonavir ( RTV ) produce adequate drug exposure pregnancy compare drug exposure historical data human immunodeficiency virus ( HIV ) infect participant .</brief_summary>
	<brief_title>Pharmacokinetics Atazanavir/Ritonavir HIV-1 Infected Pregnant Women</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>HIVinfected pregnant woman &gt; 18 year age Between week 12 32 gestation CD4 &gt; 200 cells/mmÂ³ Treatmentnaive HIV RNA &gt; 400 c/mL , HAART HIV RNA &lt; 50 c/mL , previously treat ATV ( &lt; 3 week ) HIV RNA &gt; 400 c/mL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HIV-1 infect pregnant woman , either treatment naive ATV/RTV combine ZDV/3TC</keyword>
</DOC>